GILEAD SCIENCES INC

Explore how Gilead Sciences’ new HSBC “buy” rating and WHO‑backed remdesivir Ebola trial signal strong growth and global health impact.

Gilead Sciences’ 2026 Rule 144 filings reveal senior execs’ planned share sales, offering transparent insight into leadership moves and company equity strategy.

Gilead Sciences expands oncology with Arcellx acquisition and boosts its HIV lineup using a single‑tablet bictegravir‑lenacapavir regimen, positioning it ahead of competitors.

Gilead Sciences sees split institutional sentiment and modest analyst upside; investors weigh pipeline strength against market volatility and a tight $145 price target.

Gilead Sciences sees a mix of institutional buys and insider sell‑offs; UBS turns bullish amid a strong biopharma outlook, keeping investors watching its near‑52‑week high.

Gilead Sciences faces mixed clinical news: Trodelvy misses breast‑cancer endpoints but Livdelzi shows steady liver‑disease benefits, shaping investor outlook and stock moves.

Gilead Sciences is poised for a paradigm shift after reporting landmark results from the ASCENT-03 trial of Trodelvy, a breakthrough therapy for metastatic triple-negative breast cancer, amidst a bullish market and an insider sale that raises questi…

Gilead Sciences Inc. reports strong Q2 2025 performance, exceeding market estimates with a net income of $1.9 billion and revising its 2025 guidance upwards due to its successful HIV treatment sales.